TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients

Condition:   Carcinoma, Hepatocellular Interventions:   Device: TACE;   Drug: Anlotinib Hydrochloride Sponsor:   Zhejiang Cancer Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials